IP Library Assignment 029198/0345
Patent Assignment
Reel/Frame 029198/0345

Change of Name

Recorded: 2012-10-25 Pages: 5
Assignor
AMYLIN PHARMACEUTICALS, INC.
Executed: 2012-08-08
Assignee
AMYLIN PHARMACEUTICALS, LLC
9360 TOWNE CENTRE DRIVE, ATTN: INTELLECTUAL PROPERTY GROUP, SAN DIEGO, CALIFORNIA, 92121
Covered Properties (20)
Pharmaceutical Compositions Containing Exendins
Patent: 7,297,761 →
Application: 10/894,999 →
Publication: US 2005/0215469
Exendins and Exendin Agonists for Weight Reduction and Obesity
Patent: 7,741,269 →
Application: 10/895,909 →
Publication: US 2005/0043238
Exendin Pharmaceutical Compositions
Patent: 7,521,423 →
Application: 10/896,244 →
Publication: US 2004/0266692
Metabolic Intervention with Glp-1 or Its Biologically Active Analogues to Improve the Function of the Ischemic and Reperfused Brain
Patent: 41,288 →
Application: 10/913,309 →
Pancreatic polypeptide family motifs and polypeptides comprising the same
Patent: 8,603,969 →
Application: 11/055,098 →
Publication: US 2006/0094653
Hybrid Polypeptides Having Glucose Lowering Activity
Patent: 8,076,288 →
Application: 11/206,903 →
Publication: US 2006/0293232
Exendin Analog Formulations
Patent: 7,399,489 →
Application: 11/272,488 →
Publication: US 2006/0069029
Treatment of Gestational Diabetes
Patent: 7,452,858 →
Application: 11/282,085 →
Publication: US 2006/0074012
Pancreatic Polypeptide Family Motifs, Polypeptides and Methods Comprising the Same
Patent: 7,723,471 →
Application: 11/301,744 →
Publication: US 2006/0135747
Transmucosal delivery of peptides and proteins
Application: 11/628,123 →
Publication: US 2009/0069226
Amylin Family Polypeptide-6 (Afp-6) Analogs and Methods of Making and Using Them
Patent: 7,928,060 →
Application: 11/664,750 →
Publication: US 2008/0207501
Methods for treating obesity and obesity related diseases and disorders
Application: 11/665,675 →
Publication: US 2009/0156474
Gip Analog and Hybrid Polypeptides with Selectable Properties
Patent: 8,263,545 →
Application: 11/840,921 →
Publication: US 2008/0312157
Use of Glp-1 and Agonists Thereof to Prevent Cardiac Myocyte Apoptosis
Application: 11/857,951 →
Publication: US 2009/0264352
Amylin Agonist for Treating Depression, Anxiety Disorder and Schizophrenia
Patent: 7,671,023 →
Application: 11/910,206 →
Publication: US 2008/0287355
Methods of Controlling Binge Eating Disorders
Patent: 7,879,794 →
Application: 11/910,214 →
Publication: US 2009/0062193
Pharmaceutical Formulations Comprising Incretin mimetic Peptide and Aprotic Polar Solvent
Application: 11/910,723 →
Publication: US 2008/0200383
Use of Exendin and Analogs Thereof To Delay or Prevent Cardiac Remodeling
Patent: 8,946,149 →
Application: 11/910,730 →
Publication: US 2009/0137466
Methods of Treating Obesity with two Different Anti-Obesity Agents
Patent: 8,394,765 →
Application: 11/940,317 →
Publication: US 2008/0207512
Hybrid Polypeptides with Selectable Properties
Application: 12/063,420 →
Publication: US 2009/0286723
Related Assignments (3)
Other recorded transfers of the patents in this record — the chain of ownership.
Release of Security Interest Oct 1, 2012
From: ELI LILLY AND COMPANY
To: AMYLIN PHARMACEUTICALS, INC.
Reel/Frame 029057/0342 →
Release of Security Interest Oct 2, 2012
From: ELI LILLY AND COMPANY
To: AMYLIN PHARMACEUTICALS, INC.
Reel/Frame 029062/0639 →
Amylin Pharmaceuticals, Llc Assigns an Equal and Undivided One-Half of Its Entire Right, Title and Interest to Astrazeneca Pharmaceuticals Lp Oct 26, 2012
From: AMYLIN PHARMACEUTICALS, LLC
To: ASTRAZENECA PHARMACEUTICALS LP
Reel/Frame 029195/0555 →